Teladoc Exceeds Q2 Revenue Expectations, Sets New FY22 Guidance
ByAinvest
Tuesday, Jul 29, 2025 4:49 pm ET1min read
TDOC--
The company's adjusted EBITDA, a measure of operating profitability, fell 23% to $69.3 million, but this was also above the consensus estimate of $63.50 million [1]. Teladoc attributed the revenue decline primarily to challenges in its direct-to-consumer market segment, BetterHelp, which saw a 9% YoY decrease in revenue to $240.4 million [2].
Teladoc's CEO, Chuck Divita, expressed satisfaction with the company's performance, stating that the results reflect "continued disciplined execution and builds on our solid results from the first quarter" [2]. The company also secured a $300 million credit facility to enhance financial flexibility [1].
For the third quarter (Q3) 2025, Teladoc expects revenue between $614 million and $636 million, with a GAAP loss of $0.20 to $0.35 per share. The full-year 2025 revenue guidance was lifted to $2.52 billion at the midpoint, with a GAAP loss of $1.18 per share [2].
Analysts remain cautiously optimistic, with an average rating of "hold" and a breakdown of recommendations including 5 "strong buy" or "buy," 22 "hold," and no "sell" or "strong sell" [1]. The median 12-month price target for Teladoc Health Inc. stands at $8.38, about 2.1% above its July 28 closing price of $8.20 [1].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLX9CB307:0-teladoc-q2-revenue-down-2-but-beats-expectations/
[2] https://www.investing.com/news/earnings/teladoc-shares-jump-6-on-narrower-than-feared-q2-loss-revenue-beats-93CH-4158464
Teladoc Health (TDOC) reported Q2 CY2025 results exceeding revenue expectations, with sales of $631.9 million, a 1.6% YoY decline. The company's GAAP loss of $0.19 per share was 27.8% above analysts' consensus estimates. Teladoc slightly lifted its revenue guidance for the full year to $2.52 billion at the midpoint and expects a GAAP loss of $1.18 per share.
Teladoc Health Inc. (NYSE: TDOC) reported its second-quarter (Q2) 2025 financial results, revealing a 1.6% year-over-year (YoY) decline in revenue to $631.9 million, which exceeded analysts' expectations [1]. The company's GAAP loss of $0.19 per share was 27.8% above the consensus estimate of $0.26 per share, driven by a 4% YoY increase in the Integrated Care segment and a 9% YoY decline in the BetterHelp segment [2].The company's adjusted EBITDA, a measure of operating profitability, fell 23% to $69.3 million, but this was also above the consensus estimate of $63.50 million [1]. Teladoc attributed the revenue decline primarily to challenges in its direct-to-consumer market segment, BetterHelp, which saw a 9% YoY decrease in revenue to $240.4 million [2].
Teladoc's CEO, Chuck Divita, expressed satisfaction with the company's performance, stating that the results reflect "continued disciplined execution and builds on our solid results from the first quarter" [2]. The company also secured a $300 million credit facility to enhance financial flexibility [1].
For the third quarter (Q3) 2025, Teladoc expects revenue between $614 million and $636 million, with a GAAP loss of $0.20 to $0.35 per share. The full-year 2025 revenue guidance was lifted to $2.52 billion at the midpoint, with a GAAP loss of $1.18 per share [2].
Analysts remain cautiously optimistic, with an average rating of "hold" and a breakdown of recommendations including 5 "strong buy" or "buy," 22 "hold," and no "sell" or "strong sell" [1]. The median 12-month price target for Teladoc Health Inc. stands at $8.38, about 2.1% above its July 28 closing price of $8.20 [1].
References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_PLX9CB307:0-teladoc-q2-revenue-down-2-but-beats-expectations/
[2] https://www.investing.com/news/earnings/teladoc-shares-jump-6-on-narrower-than-feared-q2-loss-revenue-beats-93CH-4158464
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet